Solution-based studies on the contact between the complement receptor 3 ligand-binding domain and simvastatin.

Area of Science:

• Pharmacology
• Immunology
• Biochemistry

Background:

• Simvastatin, a cholesterol-lowering drug, exhibits anti-inflammatory effects by targeting CD18 integrins.
• Lymphocyte-associated antigen (LFA)-1 and complement receptor 3 (CR3) are key CD18 integrins involved in immune responses.
• Simvastatin's inhibitory mechanisms on LFA-1 and CR3 have been proposed but require further elucidation.

Purpose of the Study:

• To investigate the distinct mechanisms by which simvastatin inhibits LFA-1 and CR3.
• To compare the inhibitory potencies of simvastatin's lactone (simvastatin-lac) and carboxylate (simvastatin-carbox) forms on CR3.
• To evaluate the functional consequences of simvastatin-carbox inhibition on CR3-mediated functions and in an in vivo stroke model.

Main Methods:

• Affinity measurements (K_D) of simvastatin-carbox for the αM integrin I (αMI) domain.
• Inhibition assays of CR3 binding to iC3b.
• Assessment of simvastatin's neuroprotective and anti-inflammatory effects in a middle cerebral artery occlusion (MCAO) animal model.

Main Results:

• Simvastatin-carbox showed weak affinity (K_D ≈ 650 μM) for the αMI domain, significantly lower than simvastatin-lac's inhibitory concentration (50 μM).
• Simvastatin-carbox did not inhibit CR3 binding to iC3b and lacked efficacy in the MCAO stroke model.
• Simvastatin-lac effectively inhibits both LFA-1 and CR3 through distinct allosteric and potentially ternary complex-mediated mechanisms.

Conclusions:

• Simvastatin-lac antagonizes LFA-1 via allosteric binding to the αI domain.
• Simvastatin-lac inhibits CR3 through a distinct mechanism involving a ternary complex formation, with the carboxylate form showing weak affinity.
• The anti-inflammatory and neuroprotective effects observed in previous studies are likely attributable to simvastatin-lac, not simvastatin-carbox.